FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106046752> ?p ?o ?g. }

• W2106046752 endingPage "1226" @default.
• W2106046752 startingPage "1219" @default.
• W2106046752 abstract "Whether glycaemic control may result in a reduction of cardiovascular (CV) risk has been a matter of continuous discussion and investigation. Epidemiological analyses have extensively suggested a relationship between glycaemic control and CV events; however, the results of intervention trials have been less conclusive. The UKPDS reported a 16% reduction in the risk of myocardial infarction, but this reduction was not statistically significant. The results of the Kumamoto and PROactive studies could not allow any firm conclusions to be drawn either, because of limited size and the defined primary endpoint, respectively. The results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trials and the Veteran Administration Diabetes Trial (VADT) were published in rapid succession over the second half of 2008 and at the beginning of 2009. A total number of almost 25,000 type 2 diabetic patients were recruited in these three trials, which assessed the effect of intensive glycaemic control vs conventional treatment on well-defined CV endpoints. In spite of the achievement and maintenance of strict glycaemic control (HbA1c <7.0%), no beneficial effect of intensive therapy was apparent in any of the studies. At the same time these results were presented, the results of an analysis of the 10 year follow-up of the UKPDS also became available and provided a more optimistic view of the potential benefit of achieving good glycaemic control. The relative risk reductions for myocardial infarction and all-cause mortality were significantly lower in the patients who initially received the intensive treatment compared with those in the conventional treatment arm. Moreover, the initial benefit in terms of microvascular complications observed at the end of the intervention trial remained unaltered at follow-up. Once again the debate on the importance of glycaemic control in preventing macrovascular complications remains unsettled. These results, however, require some reconciliation, and the objective of this commentary is to analyse a series of elements, including the changes in the treatment approach to CV risk factors in type 2 diabetes, the effect of glucose-lowering agents, and the characteristics of the patients included in the different trials, that should be taken into account when interpreting the results of intervention trials in type 2 diabetes." @default.
• W2106046752 created "2016-06-24" @default.
• W2106046752 creator A5034383160 @default.
• W2106046752 date "2009-04-17" @default.
• W2106046752 modified "2023-09-27" @default.
• W2106046752 title "Megatrials in type 2 diabetes. From excitement to frustration?" @default.
• W2106046752 cites W1526927233 @default.
• W2106046752 cites W172609984 @default.
• W2106046752 cites W1752045965 @default.
• W2106046752 cites W1873110099 @default.
• W2106046752 cites W1967265218 @default.
• W2106046752 cites W1970710636 @default.
• W2106046752 cites W1974785275 @default.
• W2106046752 cites W1985626263 @default.
• W2106046752 cites W19857607 @default.
• W2106046752 cites W2029084557 @default.
• W2106046752 cites W2031110940 @default.
• W2106046752 cites W2066941565 @default.
• W2106046752 cites W2071740677 @default.
• W2106046752 cites W2076679703 @default.
• W2106046752 cites W2078089300 @default.
• W2106046752 cites W2082724449 @default.
• W2106046752 cites W2083531457 @default.
• W2106046752 cites W2104600471 @default.
• W2106046752 cites W2108461905 @default.
• W2106046752 cites W2114349038 @default.
• W2106046752 cites W2124701241 @default.
• W2106046752 cites W2139634859 @default.
• W2106046752 cites W2141713511 @default.
• W2106046752 cites W2145578924 @default.
• W2106046752 cites W2146643639 @default.
• W2106046752 cites W2158666727 @default.
• W2106046752 cites W2159969745 @default.
• W2106046752 cites W2160711683 @default.
• W2106046752 cites W2164235476 @default.
• W2106046752 cites W2171294019 @default.
• W2106046752 cites W2188846692 @default.
• W2106046752 cites W2337454357 @default.
• W2106046752 cites W2471605942 @default.
• W2106046752 cites W2769264260 @default.
• W2106046752 cites W4235291177 @default.
• W2106046752 cites W71525847 @default.
• W2106046752 doi "https://doi.org/10.1007/s00125-009-1352-5" @default.
• W2106046752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19373446" @default.
• W2106046752 hasPublicationYear "2009" @default.
• W2106046752 type Work @default.
• W2106046752 sameAs 2106046752 @default.
• W2106046752 citedByCount "116" @default.
• W2106046752 countsByYear W21060467522012 @default.
• W2106046752 countsByYear W21060467522013 @default.
• W2106046752 countsByYear W21060467522014 @default.
• W2106046752 countsByYear W21060467522015 @default.
• W2106046752 countsByYear W21060467522016 @default.
• W2106046752 countsByYear W21060467522017 @default.
• W2106046752 countsByYear W21060467522018 @default.
• W2106046752 countsByYear W21060467522019 @default.
• W2106046752 countsByYear W21060467522020 @default.
• W2106046752 countsByYear W21060467522021 @default.
• W2106046752 countsByYear W21060467522022 @default.
• W2106046752 crossrefType "journal-article" @default.
• W2106046752 hasAuthorship W2106046752A5034383160 @default.
• W2106046752 hasBestOaLocation W21060467521 @default.
• W2106046752 hasConcept C126322002 @default.
• W2106046752 hasConcept C134018914 @default.
• W2106046752 hasConcept C168563851 @default.
• W2106046752 hasConcept C177713679 @default.
• W2106046752 hasConcept C203092338 @default.
• W2106046752 hasConcept C2777180221 @default.
• W2106046752 hasConcept C2779134260 @default.
• W2106046752 hasConcept C2780920962 @default.
• W2106046752 hasConcept C500558357 @default.
• W2106046752 hasConcept C535046627 @default.
• W2106046752 hasConcept C555293320 @default.
• W2106046752 hasConcept C71924100 @default.
• W2106046752 hasConceptScore W2106046752C126322002 @default.
• W2106046752 hasConceptScore W2106046752C134018914 @default.
• W2106046752 hasConceptScore W2106046752C168563851 @default.
• W2106046752 hasConceptScore W2106046752C177713679 @default.
• W2106046752 hasConceptScore W2106046752C203092338 @default.
• W2106046752 hasConceptScore W2106046752C2777180221 @default.
• W2106046752 hasConceptScore W2106046752C2779134260 @default.
• W2106046752 hasConceptScore W2106046752C2780920962 @default.
• W2106046752 hasConceptScore W2106046752C500558357 @default.
• W2106046752 hasConceptScore W2106046752C535046627 @default.
• W2106046752 hasConceptScore W2106046752C555293320 @default.
• W2106046752 hasConceptScore W2106046752C71924100 @default.
• W2106046752 hasIssue "7" @default.
• W2106046752 hasLocation W21060467521 @default.
• W2106046752 hasLocation W21060467522 @default.
• W2106046752 hasOpenAccess W2106046752 @default.
• W2106046752 hasPrimaryLocation W21060467521 @default.
• W2106046752 hasRelatedWork W1993780631 @default.
• W2106046752 hasRelatedWork W2008950754 @default.
• W2106046752 hasRelatedWork W2012438884 @default.
• W2106046752 hasRelatedWork W2108606693 @default.
• W2106046752 hasRelatedWork W2133122377 @default.
• W2106046752 hasRelatedWork W2319635624 @default.
• W2106046752 hasRelatedWork W2395472652 @default.

• next